INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia which is characterized by a decline in cognitive skills that affects a person's ability to perform everyday activities. Estimated 5.4 million people in the United States are living with AD. It is the fifth-leading cause of death among those age 65 and older (Alzheimer's Association, 2016) . Although some drugs showing effectiveness to mitigate the symptoms from getting worse for a limit time, no treatment can stop the disease. Heritability for the AD was estimated up to 79% (Gatz et al., 2006) . However, the current finding of AD-associated genetic variants is not enough to fully explain the AD signal pathway in sufficient detail.
During recent years, with the rapid advance of next-generation DNA sequencing, identify disease-related mutation from large data set and develop treatment become possible (Cheng et al., 2016a (Cheng et al., , 2018a . Genome-wide comparison studies (GWASs) have identified a significant amount of common genetic variants associated with complex traits and diseases (Welter et al., 2014; Hu et al., 2017a,b) . Many previous studies have identified genes such as APOE (Mahoney-Sanchez et al., 2016; Liao et al., 2017) on chromosome 19. However, the causal relation of those associated genes and variants remain unclear. For example, recent study and data showed that a female with the APOE gene under greater risk than a male with the APOE gene (Cacciottolo et al., 2016; Mazure and Swendsen, 2017) . This strongly indicates that we have little knowledge about how this risk factor effect people.
With GWAS summary data provided by the International Genomics of Alzheimer's Project (IGAP) (Lambert et al., 2013) , we are able to study AD in great detail. For a complex disease such as AD, the top single nucleotide polymorphisms (SNPs) often located in the non-coding region, hard to know which gene is modified by that mutation and many significant SNPs are in high linkage disequilibrium (LD) with non-significant SNPs, plus many associated SNPs are more likely to locate in expression regulation region of the disease causal gene (Nicolae et al., 2010; Karch et al., 2016) . To identify disease-associated genes, we used the transcriptome-wide association study (TWAS) (Gusev et al., 2016 ) method which integrates GWAS summarization level data, expression level data from human tissue. TWAS method can eliminate potential confounding and find disease causal gene by focusing only on expression trait linking related by genetic variation; it can also increase statistical power from the lower multiple-testing burden and the noise reduction of gene expression from environmental factors (Gusev et al., 2016) .
Previous studies have pointed out at AD is closely related to autoimmune disorders (D'Andrea, 2005; Carter, 2010) . After detecting possible disease causal gene for AD, we manually curated existing research about the autoimmune diseases that potentially related to AD.
MATERIALS AND METHODS
Data we used for SNP-trait association is a large-scale GWAS summary data provided by IGAP with total 17,008 AD cases and 37,154 controls, include 7,055,881 SNPs, we selected 6,004,159 SNPs. Expression level data are from adipose tissue (RNA-seq), whole blood (RNA array), peripheral blood (RNA array), brain tissue (RNA-seq and RNA-seq splicing) (Raitakari et al., 2008; Nuotio et al., 2014; Wright et al., 2014; Fromer et al., 2016) . Selection method can be find in Supplementary Materials.
Transcriptome-Wide Association Study
Transcriptome-wide association study can be viewed as a test for correlation between predicted gene expression and traits from GWAS summary association data. The predicted effect size of gene expression on traits can be viewed as a linear model of genotypes with weights based on the correlation between SNPs and gene expression in the training data while accounting for LD among SNPs.
There are eight modes of causality for the relationship between genetic variant, gene expression, and traits. Scenarios Figures 1E-H should be identified as significant by TWAS and its corresponding null hypothesis is gene expression completely independent of traits ( Figures 1A-D) . By only focusing on the genetic component of expression, the instances of expressiontrait association that is not caused by genetic variation but variation in traits can be avoided. One aspect that needs to be noticed is, same as other methods, TWAS is also confounded by linkage and pleiotropy.
Performing TWAS With GWAS Summary Statistics
We integrated gene expression measurements from five tissues with summary GWAS to perform multi-tissue transcriptomewide association. In each tissue, TWAS used cross-validation to compare predictions from the best cis-eQTL to those from all SNPs at the locus. Prediction models choosing from BLUP (Lofgren et al., 1989) , BSLLM (Zhou et al., 2013) , LASSO (Tibshirani, 1997) , and elastic net (Gamazon et al., 2015) .
Transcriptome-wide association study Imputes effect size (z-score) of the expression and trait are linear combination of elements of z-score of SNPs for traits with weights. The weights, W = e,s −1 s,s , are calculated using ImpG-Summary algorithm (Pasaniuc et al., 2014) and adjusted for LD. e,s is the estimated covariance matrix between all SNPs at the locus and gene expression and s,s is the estimated covariance among all SNPs which is used to account for LD.
Standardized effect sizes (Z-scores) of SNPs for a trait at a given cis locus can be denoted as a vector Z. Also, the imputed Z-score of expression and trait, WZ, has variance. W s,s W t . Therefore, the imputation Z score of the cis genetic effect on the trait is,
Bonferroni correction is usually applied when identifying significant disease-associated gene. The standard multiple testing conducted in TWAS is 0.05/15000 (Gusev et al., 2016) . But traditional p-value cutoffs adjusted by Bonferroni correction are made too strict in order to avoid an abundance of false positive results. The thresholds like 0.05/15000 for significant genes are usually chosen so that the probability of any single false positive among all loci tested is smaller than 0.05, which will lead to many missed findings. Instead, False Discovery Rate error measure is a more useful approach when a study involves a large number of tests, since it can identify as many significant genes as possible while incurring a relatively low proportion of false positives (Storey and Tibshirani, 2003) . For each tissue, we used the Benjamini and Hochberg procedure (Benjamini and Hochberg, 1995) in addition to the Bonferroni correction for all gene tested. The Benjamini and Hochberg procedure is one of false discovery rate procedures that are designed to control the expected proportion of false positives. It is less stringent than the Bonferroni correction, thus has greater power. Since this is study is more exploratory, we can pay more risk of type I error for larger statistical power. It works as follows: Put individual p-values in ascending order and assign ranks to the p-values.
(1) Calculate each individual Benjamini and Hochberg critical value with formula k m α, where k is individual p-value's rank, m is total number of tests and α is the false discovery rate.
(2) Find the largest k such that P k ≤ k m α and reject the null hypothesis for all H i for i = 1, ...k.
RESULTS
To determine which gene is significantly associated with AD, we first performed strict multiple testing Bonferroni correction (pvalue < 0.05/15000). We found 15 significant genes ( Table 1) , 11 of them has identified by previous studies of AD. In order to increase the search range, we performed false discovery rate under the same alpha (0.05). After the Benjamini and Hochberg procedure (Benjamini and Hochberg, 1995) , we found 29 additional genes ( Table 2) . Nine of those genes has previously identified to be related to AD.
PVRL2 (p-value 4.92 * 10ˆ−34 in Brain (CMC) RNA-seq, also known as NECTIN2) is a well-known gene for AD. This gene encodes a single-pass type I membrane glycoprotein and interact with AOPE gene (Kulminski et al., 2018) . TOMM40 [p-value 1.13 * 10ˆ−25 in Whole Blood (YFS) RNA Array] is also located adjacent to APOE. It has been identified by previous studies worldwide as AD related gene (Lyall et al., 2014; Goh et al., 2015; Mise et al., 2017) . It is the central and essential component of the translocase of the outer mitochondrial membrane (Humphries et al., 2005) . This confirmed that mitochondrial dysfunction plays a significant role in AD-related pathology (Swerdlow and Khan, 2004; Roses et al., 2016) .
Other highly connected genes function group identified are BIN1 [p-value 1.18 × 10 −6 in Whole Blood ( (Souliotis et al., 2016; Al-Sweel et al., 2017; Javid et al., 2018) . CEACAM19 gene located in chromosome 19, a previous study showed high expression of CEACAM19 for patients with breast cancer (Estiar et al., 2017) ; CLPTM1 has been shown to increase the risk of lung cancer and melanoma (Llorca-Cardenosa et al., 2014; Lee et al., 2017) . Both CEACAM19 and CLPTM1 gene are located in chromosome 19 and near APOE gene. More detailed studies are needed to investigate the relationship between those genes and whether CLPTM1 and CEACAM19 are disease causal gene.
New Identified Genes

DISCUSSION
APOE Related Genes
Although APOE is not reported to be significant in any tissue, not enough evidence to conclude that APOE is not related to AD. Since each SNP has a weight assigned regarding the expression in TWAS study, even two genes are both significantly related to a disease, it is very likely only one of them will be showing significant in TWAS. TOMM40 (Figure 2 , p-value 1.13 × 10 −25 ) gene located adjacent to APOE (Pomara et al., 2011) , and has a strong LD with APOE gene (Yu et al., 2007) , hence TWAS didn't detect this APOE does not imply it is not disease causal gene. APOE and TOMM40 may interact to affect AD pathology such as mitochondrial dysfunction (David et al., 2005; Roses et al., 2013) . Further study is needed to show causal relation in detail. PICALM [p-value 2084 × 10 −7 in Peripheral Blood (NTR) RNA Array] and PTK2B [p-value 9.93 × 10 −8 in Peripheral Blood (NTR) RNA Array; p-value 2.89 × 10 −6 in Whole Blood (YFS) RNA Array] are also related to APOE and TOMM40 gene according to previous studies (Carter, 2011; Gharesouran et al., 2014; Morgen et al., 2014; Han et al., 2017) .
Association With Autoimmune Diseases
Complex disease such as AD, often shares common pathways or causal genes with other diseases (Hu et al., 2017c) . For instance, TOMM40 is a shared disease-associated gene between AD and Type II diabetes (Greenbaum et al., 2014) . Recent studies showing autoimmune diseases have closed relation with AD (D'Andrea, 2005; Lehrer and Rheinstein, 2015; Wotton and Goldacre, 2017) . Among all the genes we identified through TWAS method, eight of them are related to autoimmune diseases.
As shown in Figure 3 , PICALM, PVRL2, PVR, and CLU have shown to be related to systemic, an autoimmune disease characterized by vascular injury and debilitating tissue fibrosis (Xia et al., 2010; Ryu et al., 2014; Tsou et al., 2016; van Luijn et al., 2016) . CR1 and CLU gene are related to thymus function which could potentially cause an autoimmune disorder (French et al., 1992; Pekalski et al., 2017) . MLH3 and BIN1 gene have shown to be associated with Lupus, another severe autoimmune disease (Armstrong et al., 2014; Souliotis et al., 2016) . Although with existing result, we don't have enough evidence to prove these genes are both disease causal genes for AD and autoimmune disease, further research from areas such as metabolomics and proteomics is needed to study the disease association between AD and autoimmune diseases (Cheng et al., 2016b (Cheng et al., , 2017 Hu et al., 2018) .
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